

Neopharmed Gentili presented two important social responsibility projects at the “Third National Conference of Voluntary Associations” in Bologna organised by Diabete Italia Onlus: “Renewing your driving licence if you have diabetes” and “Gestational Diabetes: focusing on women’s problems”

Bologna, 11-12 May 2013 - During the Third National Conference of Voluntary Associations held in Bologna by Diabete Italia Onlus, in the presence of representatives of the major voluntary sector associations and major scientific and institutional figures, Neopharmed Gentili presented two important corporate social responsibility projects: “Renewing your driving licence if you have diabetes” and “Gestational Diabetes: focusing on women’s problems.” *In health care, the patient is too often seen in terms of a bed occupied in a hospital and not as a person. Industry must help start the process of regaining a sense of responsibility and this is the reason why our company has decided to give support and practical help to improve the lives of many people with diabetes,”* said Francesco Dantini, Group Market Access Manager.

- Renewing your driving licence if you have diabetes (pdf attached)

The Ministry of Infrastructure and Transport decree of 30 November 2010, transposing Directive 2009/112/EC on renewing or obtaining a driving license for people with diabetes is interpreted in different ways because not all Italian regions have standardised rules and forms, so depending on their province a diabetic may be authorised to drive for 10 years or for just one year. To try to clarify the situation and help people with diabetes, Neopharmed Gentili has produced and distributed to all interested bodies such as GP surgeries, local health services, Medical Legal Committees and ACI (Italian Automobile Club) Delegations explanatory leaflets and posters produced in association with Dr Miccoli of Cisanello Hospital in Pisa.

- Gestational Diabetes: focusing on women’s problems (pdf attached)

Motherhood is clearly one of the most important and emotional events in the life of a woman, but a metabolic disorder called “gestational diabetes” is becoming increasingly common. This problem involves an abnormal rise in blood sugar and a series of problems for the expectant mother and baby. Unfortunately, there is not much medical and scientific information on this, so Neopharmed Gentili has produced and distributed leaflets that answer the most common questions asked by women with gestational diabetes post diagnosis. The material has been translated into several languages and is broad enough to meet the needs of every pregnant woman, both with regard to calorie intake and different physical activities.



The Bologna conference heard the company outline its commitment and efforts. Mediolanum Farmaceutici believes in the future and is engaged in projects of great individual and social responsibility. Since 1972, the year in which it was founded, Mediolanum Farmaceutici has gradually established itself in the health field, in the research, testing, manufacturing and marketing of original, innovative, effective and safe drugs.

Despite these tough times with government cuts and an economic crisis that has also affected the pharmaceutical industry, the company's significant and continuing investment of resources, skills and personnel, has confirmed, with rigour and pride, its thoroughly Italian identity as an agile, dynamic, serious firm, capable of dealing with the chemical and pharmaceutical giants operating in what is now known as the "single world market".

It has already achieved significant results in the fields of cardiovascular, neurological, hormonal and infectious diseases.

The stakes - the quality of life - are high and concern everyone. Indeed, health is the most valuable collective good, something in which Mediolanum Farmaceutici has always invested all its resources and is still committed to doing so.

MEDIOLANUM FARMACEUTICI - www.mediolanum-farma.it

Mediolanum Farmaceutici S.p.A., established in Milan in 1972 by Rinaldo Del Bono, with a turnover in Italy of 170 million Euros is one of the top ten Italian owned pharmaceutical companies (IMS World Review, 2011). It is currently the lead company of a group including Neopharmed Gentili, Vantapharma, Mediolanum Healthcare, Cristalfarma and Integra in Italy, and Laboratoires Leurquin-Mediolanum and Ferlux-Mediolanum in France. With a staff of about 600 people it is a major player in the Italian pharmaceutical market. It is present in many therapeutic areas ranging from vascular to cardiometabolic, to the respiratory system, as well as antibiotics, OTC and supplements segments. ~~Mediolanum is also investing in other important therapeutic fields with its ambitious and innovative research projects.~~

Media Contacts:

Ottavia Landi di Chiavenna

External Relations Manager

MEDIOLANUM Farmaceutici Spa

Tel +39 02.89.132.247

Mobile +39.342.3409572

Email: o.landi@mediolanum-farma.com